Skip navigation
Home
Menu
Menu
Study
Student life
Research and innovation
Global
About us
Staff
Students
Search the site
Centre of Excellence for Long-acting Therapeutics
Menu
About us
LONGEVITY
HALo
Nanotherapeutics Hub
Teoreler
PKRxiv
LAPaL
Blog
News
Events
Contact us
News
Long-acting injectable for schizophrenia approved in the EU
12 April 2024
Positive phase 2 study of zilebesiran for patients with hypertension
12 April 2024
Innovative Long-acting Drug Delivery Platform Implanted in Eyes
05 April 2024
Medicenna Announce First Patient with Advanced Solid Tumours Dosed in ABILITY-1 Study of MDNA11 Combination with KEYTRUDA® (pembrolizumab)
16 February 2024
Long-acting antiretroviral therapy (ART) maintains HIV virologic suppression regardless of obesity status
16 February 2024
Long-acting HIV Antiretrovirals adopted in Botswana
09 February 2024
Global Long-acting Therapeutics News from January 2024
29 January 2024
Phase 1 data of mdc-TJK investigational long-acting injectable of olanzapine for schizophrenia patients, exhibited favourable characteristics
26 May 2023
Phase 3 Study Finds Dupilumab Reduces COPD Exacerbations in Patients With Type 2 Inflammation
26 May 2023
Newer stories
Older Stories